SCHEMBL7235333

SCHEMBL7235333

CCN1C(=O)C(C(=O)OC)c2cc(C3(CC)OCCO3)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.43
ALDH1A1 P00352 7/20 0.39
TSHR P16473 2/20 0.39
GAA P10253 2/20 0.39
KDM4E B2RXH2 2/20 0.39
CYP3A4 P08684 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
HKDC1 Q2TB90 7/20 0.37
UBE2I P63279 3/20 0.37
SAE1 Q9UBE0 3/20 0.37
UBA2 Q9UBT2 3/20 0.37
MEN1 O00255 8/20 0.36
KMT2A Q03164 8/20 0.36
CFTR P13569 3/20 0.36
GOPC Q9HD26 3/20 0.36
CASP6 P55212 3/20 0.35
POLB P06746 1/20 0.35
HDAC2 Q92769 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7236836 0.88 USP2 (0.43) USP2ALDH1A1TSHRGAAKDM4E
SCHEMBL9667435 0.79 USP2 (0.34) USP2ALDH1A1TSHRGAAKDM4E
SCHEMBL9667195 0.79 USP2 (0.38) USP2ALDH1A1TSHRGAAKDM4E
SCHEMBL7234553 0.76 ALDH1A1 (0.40) USP2ALDH1A1TSHRGAAKDM4E
SCHEMBL7234179 0.75 CHRM2 (0.37) USP2ALDH1A1TSHRGAAKDM4E
SCHEMBL9667378 0.75 CASP3 (0.48) USP2ALDH1A1TSHRGAAKDM4E
SCHEMBL7237207 0.74 MEN1 (0.38) ALDH1A1GAACYP3A4CYP1A2CYP2D6
SCHEMBL10747205 0.73 ALDH1A1 (0.40) ALDH1A1TSHRGAACYP3A4CYP1A2
SCHEMBL9667216 0.72 KMT2A (0.46) USP2ALDH1A1TSHRGAAKDM4E
SCHEMBL9667758 0.71 USP2 (0.43) USP2ALDH1A1TSHRGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030004162-A1 Use of glycogen phosphorylase inhibitors TREADWAY JUDITH L (US) 2003-01-02 US disclosed
US-20020031816-A1 METHOD OF INHIBITION OF HUMAN GLYCOGEN PHOSPHORYLASE PFIZER PRODUCTS INC. 2002-03-14 US disclosed
EP-1136071-A2 Use of glycogen phosphorylase inhibitors Pfizer Products Inc. (US) 2001-09-26 EP disclosed
EP-0978279-A1 Inhibitors of human glycogen phosphorylase Pfizer Products Inc. (US) 2000-02-09 EP disclosed
US-5998463-A Glycogen phosphorylase inhibitors PFIZER INC (US) 1999-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004162-A1 Use of glycogen phosphorylase inhibitors PYGL, PYGM, GYS2 USP2 1461/4885ALDH1A1 2056/4885TSHR 4593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.